GW Pharmaceuticals is conducting a clinical trial on the effectiveness of its CBD drug in treating tremors in Parkinson’s Disease.
The company said it expects to complete the study in June 2019.
The first stage looks at the safety and tolerability of a target dose of 20 mg/kg/day in 10 participants. It said the target dosage is based on the company’s experience.
The 100 mg/ml oral solution of strawberry-flavored liquid, in sesame oil, is supplied by GW Pharmaceuticals.
Stage two of the study will involve 50 individuals.
The company said that CBD has been shown to be relatively safe and that it reduces tremor, anxiety and psychosis.
Studies also show CBD has anti-inflammatory, anticonvulsant, anti-oxidant, anxiolytic and antipsychotic properties, it said.
The clinical trials are being conducted at Colorado University in collaboration with the Department of Public Health and Environment
It’s not the first time that CBD has been studied as a possible treatment for Parkinsons.
In a 2015 paper published by the International Parkinson and Movement Disorder Society, the departments of neurology at the University of Colorado School of Medicine and the Baylor College of Medicine in Houston said that clinical trials suggested “a possible benefit of cannabinoids for tics” associated with neurological disorders.
They said that cannabinoid receptors were increased in areas of the brain where lesions had formed.
Scientific studies have also provided evidence that cannabinoids may help protect areas of the brain that are affected in patients with Alzheimer’s, Parkinson’s, Huntington’s Disease and other movement disorders.
Other researchers found that the genetic mutation responsible for the most prevalent type of late-onset hereditary Parkinson’s disease responded to targeted application of cannabinoids.